Om Manchanda, CEO, Dr Lal Pathlabs says, regulations in the diagnosis space have been limited and there exists scope to extend them to the diagnostics market, which is a highly fragmented. Money Control, 2 months ago
Diagnostic major Thyrocare Technologies, listed at a 49 per cent premium over its initial public offering (IPO) price of Rs 446 last Monday, is trading near Rs 630. The trend is similar to the one seen with Dr Lal PathLabs, which listed a few months ...Smart Investor, 1 week ago
Thyrocare Technologies, the diagnostic major, listed at a 49% premium over its IPO price of Rs 446 last Monday and is now at Rs 630 levels. The trend is similar to the one seen with Dr Lal PathLabs which listed a few months back. Compared to the IPO ...Business Standard India, 1 week ago
on your WebpageAdd Widget >Get your members hooked!